208 related articles for article (PubMed ID: 31775111)
1. Novel deazaflavin tyrosyl-DNA phosphodiesterase 2 (TDP2) inhibitors.
Kiselev E; Ravji A; Kankanala J; Xie J; Wang Z; Pommier Y
DNA Repair (Amst); 2020 Jan; 85():102747. PubMed ID: 31775111
[TBL] [Abstract][Full Text] [Related]
2. Novel Deazaflavin Analogues Potently Inhibited Tyrosyl DNA Phosphodiesterase 2 (TDP2) and Strongly Sensitized Cancer Cells toward Treatment with Topoisomerase II (TOP2) Poison Etoposide.
Kankanala J; Ribeiro CJA; Kiselev E; Ravji A; Williams J; Xie J; Aihara H; Pommier Y; Wang Z
J Med Chem; 2019 May; 62(9):4669-4682. PubMed ID: 30998359
[TBL] [Abstract][Full Text] [Related]
3. Deazaflavin Inhibitors of TDP2 with Cellular Activity Can Affect Etoposide Influx and/or Efflux.
Komulainen E; Pennicott L; Le Grand D; Caldecott KW
ACS Chem Biol; 2019 Jun; 14(6):1110-1114. PubMed ID: 31091068
[TBL] [Abstract][Full Text] [Related]
4. Deazaflavin Inhibitors of Tyrosyl-DNA Phosphodiesterase 2 (TDP2) Specific for the Human Enzyme and Active against Cellular TDP2.
Marchand C; Abdelmalak M; Kankanala J; Huang SY; Kiselev E; Fesen K; Kurahashi K; Sasanuma H; Takeda S; Aihara H; Wang Z; Pommier Y
ACS Chem Biol; 2016 Jul; 11(7):1925-33. PubMed ID: 27128689
[TBL] [Abstract][Full Text] [Related]
5. Depletion of tyrosyl DNA phosphodiesterase 2 activity enhances etoposide-mediated double-strand break formation and cell killing.
Kont YS; Dutta A; Mallisetty A; Mathew J; Minas T; Kraus C; Dhopeshwarkar P; Kallakury B; Mitra S; Üren A; Adhikari S
DNA Repair (Amst); 2016 Jul; 43():38-47. PubMed ID: 27235629
[TBL] [Abstract][Full Text] [Related]
6. Cancer sensitizing effect of deazaflavin analogs is associated with increased intracellular drug accumulation.
Belhadj Z; Offei S; Jacobson BA; Cambron D; Kratzke RA; Wang Z; Xie J
Eur J Pharm Sci; 2024 Feb; 193():106686. PubMed ID: 38159687
[TBL] [Abstract][Full Text] [Related]
7. Repair of trapped topoisomerase II covalent cleavage complexes: Novel proteasome-independent mechanisms.
Tsuda M; Kitamasu K; Hosokawa S; Nakano T; Ide H
Nucleosides Nucleotides Nucleic Acids; 2020; 39(1-3):170-184. PubMed ID: 31608820
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and structure-activity relationship of furoquinolinediones as inhibitors of Tyrosyl-DNA phosphodiesterase 2 (TDP2).
Yu LM; Hu Z; Chen Y; Ravji A; Lopez S; Plescia CB; Yu Q; Yang H; Abdelmalak M; Saha S; Agama K; Kiselev E; Marchand C; Pommier Y; An LK
Eur J Med Chem; 2018 May; 151():777-796. PubMed ID: 29677635
[TBL] [Abstract][Full Text] [Related]
9. TDP2 promotes repair of topoisomerase I-mediated DNA damage in the absence of TDP1.
Zeng Z; Sharma A; Ju L; Murai J; Umans L; Vermeire L; Pommier Y; Takeda S; Huylebroeck D; Caldecott KW; El-Khamisy SF
Nucleic Acids Res; 2012 Sep; 40(17):8371-80. PubMed ID: 22740648
[TBL] [Abstract][Full Text] [Related]
10. Discovery, enantioselective synthesis of myrtucommulone E analogues as tyrosyl-DNA phosphodiesterase 2 inhibitors and their biological activities.
Zhang Y; Yang H; Wang FT; Peng X; Liu HY; Li QJ; An LK
Eur J Med Chem; 2022 Aug; 238():114445. PubMed ID: 35580424
[TBL] [Abstract][Full Text] [Related]
11. Repair of topoisomerase 1-induced DNA damage by tyrosyl-DNA phosphodiesterase 2 (TDP2) is dependent on its magnesium binding.
Shimizu N; Hamada Y; Morozumi R; Yamamoto J; Iwai S; Sugiyama KI; Ide H; Tsuda M
J Biol Chem; 2023 Aug; 299(8):104988. PubMed ID: 37392847
[TBL] [Abstract][Full Text] [Related]
12. TDP2/TTRAP is the major 5'-tyrosyl DNA phosphodiesterase activity in vertebrate cells and is critical for cellular resistance to topoisomerase II-induced DNA damage.
Zeng Z; Cortés-Ledesma F; El Khamisy SF; Caldecott KW
J Biol Chem; 2011 Jan; 286(1):403-9. PubMed ID: 21030584
[TBL] [Abstract][Full Text] [Related]
13. New fluorescence-based high-throughput screening assay for small molecule inhibitors of tyrosyl-DNA phosphodiesterase 2 (TDP2).
Ribeiro CJA; Kankanala J; Shi K; Kurahashi K; Kiselev E; Ravji A; Pommier Y; Aihara H; Wang Z
Eur J Pharm Sci; 2018 Jun; 118():67-79. PubMed ID: 29574079
[TBL] [Abstract][Full Text] [Related]
14. Discovery of selective inhibitors of tyrosyl-DNA phosphodiesterase 2 by targeting the enzyme DNA-binding cleft.
Kossmann BR; Abdelmalak M; Lopez S; Tender G; Yan C; Pommier Y; Marchand C; Ivanov I
Bioorg Med Chem Lett; 2016 Jul; 26(14):3232-3236. PubMed ID: 27262595
[TBL] [Abstract][Full Text] [Related]
15. Tyrosyl-DNA phosphodiesterase 2 (TDP2) repairs topoisomerase 1 DNA-protein crosslinks and 3'-blocking lesions in the absence of tyrosyl-DNA phosphodiesterase 1 (TDP1).
Tsuda M; Kitamasu K; Kumagai C; Sugiyama K; Nakano T; Ide H
DNA Repair (Amst); 2020; 91-92():102849. PubMed ID: 32460231
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and Biological Evaluation of the First Triple Inhibitors of Human Topoisomerase 1, Tyrosyl-DNA Phosphodiesterase 1 (Tdp1), and Tyrosyl-DNA Phosphodiesterase 2 (Tdp2).
Wang P; Elsayed MSA; Plescia CB; Ravji A; Redon CE; Kiselev E; Marchand C; Zeleznik O; Agama K; Pommier Y; Cushman M
J Med Chem; 2017 Apr; 60(8):3275-3288. PubMed ID: 28418653
[TBL] [Abstract][Full Text] [Related]
17. The synthesis of furoquinolinedione and isoxazoloquinolinedione derivatives as selective Tyrosyl-DNA phosphodiesterase 2 (TDP2) inhibitors.
Yang H; Zhu XQ; Wang W; Chen Y; Hu Z; Zhang Y; Hu DX; Yu LM; Agama K; Pommier Y; An LK
Bioorg Chem; 2021 Jun; 111():104881. PubMed ID: 33839584
[TBL] [Abstract][Full Text] [Related]
18. Robustadial A and B from Eucalyptus globulus Labill. and their anticancer activity as selective tyrosyl-DNA phosphodiesterase 2 inhibitors.
Zhang Y; He XZ; Yang H; Liu HY; An LK
Phytother Res; 2021 Sep; 35(9):5282-5289. PubMed ID: 34314073
[TBL] [Abstract][Full Text] [Related]
19. Proteolytic degradation of topoisomerase II (Top2) enables the processing of Top2·DNA and Top2·RNA covalent complexes by tyrosyl-DNA-phosphodiesterase 2 (TDP2).
Gao R; Schellenberg MJ; Huang SY; Abdelmalak M; Marchand C; Nitiss KC; Nitiss JL; Williams RS; Pommier Y
J Biol Chem; 2014 Jun; 289(26):17960-9. PubMed ID: 24808172
[TBL] [Abstract][Full Text] [Related]
20. Tyrosyl-DNA phosphodiesterase inhibitors: Progress and potential.
Laev SS; Salakhutdinov NF; Lavrik OI
Bioorg Med Chem; 2016 Nov; 24(21):5017-5027. PubMed ID: 27687971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
